Publication in refereed journal
香港中文大学研究人员 ( 现职)
| 莫树锦教授 (肿瘤学系) |
全文
| 数位物件识别号 (DOI) http://dx.doi.org/10.1053/j.seminoncol.2013.12.010 |
引用次数
Web of Sciencehttp://aims.cuhk.edu.hk/converis/portal/Publication/16WOS source URL
其它资讯
摘要The epidermal growth factor receptor (EGFR) mutation is a potent oncogenic driver that accounts for carcinogenesis and tumor growth of pulmonary adenocarcinoma. Targeting EGFR with tyrosine kinase inhibitors (TKIs) is highly effective in terms of tumor response rate, progression-free survival (PFS), and quality of life. Multiple randomized studies have confirmed the superiority of EGFR TKIs over platinum-based chemotherapy and established EGFR TKIs as standard first-line therapy for patients with EGFR mutation-positive non-small cell lung cancer (NSCLC). However, almost all patients will develop resistance to EGFR TKIs and post progression therapy may include a combination of local therapy, systemic chemotherapy, and second-generation EGFR TKIs. (C) 2014 Elsevier Inc. All rights reserved.
着者Mok TSK, Lee K, Leung L
期刊名称Seminars in Oncology
出版年份2014
月份2
日期1
卷号41
期次1
出版社WB Saunders
页次101 - 109
国际标準期刊号0093-7754
电子国际标準期刊号1532-8708
语言英式英语
Web of Science 学科类别Oncology; ONCOLOGY
